HomeCompareZRFY vs MRK

ZRFY vs MRK: Dividend Comparison 2026

ZRFY yields 2000000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZRFY wins by $4.879226400974806e+39M in total portfolio value
10 years
ZRFY
ZRFY
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full ZRFY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ZRFY vs MRK

📍 ZRFY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZRFYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZRFY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZRFY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZRFY
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, ZRFY beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZRFY + MRK for your $10,000?

ZRFY: 50%MRK: 50%
100% MRK50/50100% ZRFY
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ZRFY
No analyst data
Altman Z
-1990.1
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZRFY buys
0
MRK buys
0
No recent congressional trades found for ZRFY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZRFYMRK
Forward yield2000000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4.879226400974806e+39M$56.8K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$9,798.13
Total dividends collected$4.879195005460081e+39M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ZRFY vs MRK ($10,000, DRIP)

YearZRFY PortfolioZRFY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,206$366.19+$200.00MZRFY
2$3,738,731,768,458$3,738,517,757,009.35$12,650$502.35+$3738731.76MZRFY
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,407$694.19+$65315062866.92MZRFY
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$16,585$967.82+$1066400830062625.00MZRFY
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$19,342$1,363.89+$16272182796453826560.00MZRFY
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$22,913$1,947.19+$2.3205424011366188e+23MZRFY
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$27,662$2,823.89+$3.0927990661046884e+27MZRFY
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$34,159$4,173.35+$3.8524105697352695e+31MZRFY
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$43,337$6,308.80+$4.484688260147987e+35MZRFY
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$56,776$9,798.13+$4.879226400974806e+39MZRFY

ZRFY vs MRK: Complete Analysis 2026

ZRFYStock

Zerify, Inc. provides software development and services worldwide. The company develops and licenses various identification protection software products to protect computer networks from unauthorized access, as well as to protect network owners and users from cyber security attacks and data breaches. It offers ProtectID, an authentication platform to authenticate computer network users by various methods, including traditional passwords combined with a telephone, iPhone, Droid, Blackberry, PDA, multiple computer secure sessions, biometric identification, and encrypted devices, as well as through a push authentication method; and GuardedID that prevents the use of spyware/malware to collect user information. The company's products also comprise MobileTrust, an iPhone/iPad and Android device password vault that includes a password generator, as well as provides for mobile multi-factor one time password authentication; GuardedID mobile software development kit; SafeVchat video conferencing product; and PrivacyLok, which offers protective mechanisms. In addition, it provides software and hardware that are contractually licensed from other vendors, as well as additional authentication and telecommunication software devices. The company markets its products to financial service firms; healthcare related, legal services, virtual private network, technology service, and e-commerce companies; automotive; government agencies; multi-level marketing groups; and retail distributors, as well as the enterprise market. It sells its products directly to consumers through internet, distributors, resellers, third party agents, affiliates, and original equipment manufacturer agreements. The company was formerly known as StrikeForce Technologies, Inc. and changed its name to Zerify, Inc. in June 2022. Zerify, Inc. was incorporated in 2001 and is headquartered in Edison, New Jersey.

Full ZRFY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ZRFY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZRFY vs SCHDZRFY vs JEPIZRFY vs OZRFY vs KOZRFY vs MAINZRFY vs JNJZRFY vs ABBVZRFY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.